Canagliflozin
Canagliflozin is a sodium-glucose cotransporter 2 inhibitor. It reduces renal glucose reabsorption, increasing glucose excretion in urine.
Key points
- Canagliflozin acts at the kidney’s SGLT2 transporter.
- Its effects extend to fluid balance and genital or urinary infection risk.
Invokana connects canagliflozin with type 2 diabetes in the diabetes management category. Ketoacidosis, dehydration, genital infections and foot complications are prominent medicine-specific safety topics. They explain the ingredient more usefully than an editorial strength list.